Antonia Girardi, MD, Istituto Europeo di Oncologia, Milan, Italy, explores what is to come in the field of metaplastic breast cancer, as well as the optimal treatment approach for this patient population. Dr Girardi discusses the lack of novel targeted agents as an unmet need for patients with metaplastic breast cancer. This interview took place during the 17th St. Gallen International Breast Cancer Conference.